1. Scrip
  2. >>Therapy Areas

Astex Eyes First Filing For Oral Decitabine On Positive Combo Results

 
• By Ian Haydock

Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
Oral Decitabine Brings Dosing Convenience • Source: Shutterstock

Otsuka Pharmaceutical Co. Ltd. subsidiary Astex Pharmaceuticals Inc. plans to file for the US approval of ASTX727, an oral fixed-dose combination of decitabine and cedazuridine, by the end of this year, after the product met its primary endpoint in a Phase III trial.

The positive top-line results came from the 138-patient, open-label ASCERTAIN study in North America with the combo versus intravenous decitabine,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.